Top news from ATS 2024 International Conference: IPF treatments, asthma therapies
Click Here to Manage Email Alerts
Doctors from across the world gathered at this year’s American Thoracic Society International Conference in San Diego to present research on various respiratory diseases and conditions.
Of the topics discussed, presentations on asthma, idiopathic pulmonary fibrosis treatments and obstructive sleep apnea made up several of the top headlines from Healio’s coverage of the meeting.
Read these and other top news from the 2024 ATS International Conference below:
More severe OSA linked to premature aging in adults
A heightened oxygen desaturation index was significantly linked to epigenetic age acceleration determined via two epigenetic clocks, according to a cross-sectional study. Read more.
Greater hospital racial diversity linked to poorer mechanical ventilation outcomes
Patients ventilated for pneumonia or sepsis faced higher mortality odds as the racial diversity of the patient population increased, according to a poster. Read more.
Lysophosphatidic acid receptor 1 antagonist slows time to disease progression in IPF
Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation. Read more.
Tezepelumab decreases exacerbation rate, improves lung function, quality of life in COPD
Among patients with moderate to very severe COPD receiving tezepelumab (Tezspire; Amgen, AstraZeneca) vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented during a breaking news scientific symposium. Read more.
Hedgehog pathway inhibitor safe, improves lung function in IPF
After receiving a hedgehog pathway inhibitor for 12 weeks, adults with idiopathic pulmonary fibrosis had better lung function, according to a multicenter, randomized, double-blind, placebo-controlled phase 2a trial. Read more.
Metformin associated with fewer hospitalizations in children with asthma
Children with asthma who used metformin experienced decreases in asthma-related hospitalizations and oral steroid use, according to an abstract. Read more.
Asthma, type 2 inflammation associated with coronary artery disease
Type 2 inflammation and asthma were significantly associated with higher risk for coronary artery disease, according to a presentation. Read more.
Educational texts raise physicians’ confidence in treating tobacco use disorder
After receiving educational texts on tobacco use disorder treatment for 13 days, physicians felt more confident treating this disorder, according to research presented during the 2024 ATS-Association of Pulmonary and Critical Care Medicine Program Directors-Pediatric Pulmonary Training Directors Association for Clinical Educators Forum. Read more.
Anti-TSLP therapy reduces inflammation in moderate to severe asthma
A fragment antibody against thymic stromal lymphopoietin was safe and effective in reducing airway inflammation among patients with asthma, according to a presentation. Read more.
CPAP therapy lowers all-cause, cardiovascular mortality risk in OSA
Among adults with obstructive sleep apnea, positive airway pressure therapy reduced the risk for all-cause and cardiovascular mortality, according to a systematic literature review and meta-analysis. Read more.